How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,934 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

ulcers or duodenal ulcers for the treatment of resistance; 3 or 4 grade gastrointestinal bleeding / bleeding; Gastrointestinal perforation / fistula; Abdominal abscess; Infectious or inflammatory bowel disease HIV infection and/or active hepatitis B virus infection Pregnant or lactating women. Fertile patients must use effective contraception Any serious acute or chronic disease that can not be involved in the study or to influence the interpretation of the results of the study Other intervention (...) Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

122. Rifaximin to Modify the Disease Course in Sickle Cell Disease

receive any blood products within three weeks of the screening visit. Patients with uncontrolled liver disease or renal insufficiency, colitis, or inflammatory bowel disease. Patients with HIV, or other concomitant immunodeficiency. Patients on penicillin prophylaxis or antibiotics for treatment of infection. Patients with significant medical condition that require hospitalization (other than sickle cell VOC) within two months of the screening visit. Patients currently taking or has been treated (...) Rifaximin to Modify the Disease Course in Sickle Cell Disease Rifaximin to Modify the Disease Course in Sickle Cell Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rifaximin to Modify the Disease

2018 Clinical Trials

123. Delays to treatment initiation is associated with tuberculosis treatment outcomes among patients on directly observed treatment short course in Southwest Ethiopia: a follow-up study. Full Text available with Trip Pro

Delays to treatment initiation is associated with tuberculosis treatment outcomes among patients on directly observed treatment short course in Southwest Ethiopia: a follow-up study. Despite reported long delays to initiate anti-TB treatment and poor outcomes in different parts of Ethiopia and elsewhere, evidences on association between the delay and treatment outcomes are scanty.A follow up study among 735 new TB cases registered at health facilities in districts of southwest Ethiopia (...) (ARR) = 1.92, 95%CI:1.30, 2.81], HIV co-infection (ARR = 2.18, 95%CI:1.47, 3.25) and received treatment at hospital (ARR = 3.73, 95%CI:2.23, 6.25). On the other hand, lower risk of unsuccessful outcome was predicted by weight gain (ARR = 0.40, 95%CI:0.19, 0.83) and sputum smear negative conversion (ARR = 0.17,95% CI:0.09, 0.33) at the end of second month treatment.Higher risk of unsuccessful outcome is associated with prolonged days elapsed between onset of illness and treatment commencement. Hence

2018 BMC Pulmonary Medicine

124. The Clinical Course of Patients with PSA≥100 Ng/mL: Insight Into a Potential Population for Targeted PSA Screening. (Abstract)

was 8. Median age at presentation was 67.4 years (minimum, 40.8 and maximum, 90.6). Eighty-nine percent of patients were African American, 24% lived alone, 12% were homeless or incarcerated, 51% were insured by Medicare or Medicaid, and 47% were uninsured. Only 1% had human immunodeficiency virus, 19% had diabetes, and 13% had chronic kidney disease. Of the 65 newly diagnosed patients, only 23% had ever been screened and 9% were previously biopsied. Median time from presentation to death was 17.8 (...) The Clinical Course of Patients with PSA≥100 Ng/mL: Insight Into a Potential Population for Targeted PSA Screening. To characterize men presenting to a tertiary care safety-net hospital with prostate-specific antigen (PSA) values ≥100 ng/mL and to identify a potential population for targeted PSA screening.Retrospective review of 100 randomly selected patients of a total of 204 who presented to Grady Memorial Hospital from 2004 to 2011 with initial PSA ≥100 ng/mL was performed. Demographics

2018 Urology

125. Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease

Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease (FLM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03748511 Recruitment Status : Not yet recruiting

2018 Clinical Trials

126. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years Full Text available with Trip Pro

Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years Despite modern intensive care with standardized strategies against acute respiratory distress syndrome (ARDS), Pneumocystis pneumonia (PcP) remains a life-threatening disease with a high mortality rate. Here, we analyzed a large mixed cohort of immunocompromised patients with PcP, with regard to clinical course and treatment, and aimed at identifying predictors (...) of outcome.This was a single-center retrospective analysis in a tertiary care institution across 17 years. Diagnosis of PcP required typical clinical features and microbiological confirmation of Pneumocystis jirovecii. Epidemiological, clinical, laboratory and outcome data were collected from patient records.A total of 52,364 specimens from 7504 patients were sent for microbiological assessment (3653 with clinical suspicion of Pneumocystis pneumonia). PcP was confirmed in 240 patients, about half of them HIV

2018 Critical Care

127. First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. Full Text available with Trip Pro

First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. The aim of the study was to investigate the impact of first-line combined antiretroviral therapy (cART) regimen on the course of CD8 T-cell counts in human immunodeficiency virus (HIV)-infected patients.A retrospective observational study conducted on the French DAT'AIDS Cohort of HIV-infected patients.We selected 605 patients initiating a first-line cART (...) between 2002 and 2009, and which achieved a sustained undetectable HIV plasma viral load (pVL) for at least 12 months without cART modification. The evolution of CD8 T-cell counts according to cART regimen was assessed.CD8 T-cell counts were assessed in 572 patients treated with 2NRTIs+1PI/r (n= 297), 2NRTIs+1NNRTI (n= 207) and 3NRTIs (n= 68). In multivariate analysis, after 12 months of follow-up, the 3NRTIs regimen was associated with a significantly smaller decrease of CD8 T-cell count compared

2016 Medicine

128. Accelerated CD4 decline in untreated HIV-1 patients points toward increasing virulence over the course of the epidemic. (Abstract)

Accelerated CD4 decline in untreated HIV-1 patients points toward increasing virulence over the course of the epidemic. Based on the assumption that the rate of CD4 cell count loss in treatment-naïve patients is correlated with the virulence of HIV-1, we evaluated 4616 patients. Patients who entered a German national database between 1985 and 1995 had a median annual CD4 cell count loss of 48 cells/μl, whereas those registered between 1999 and 2009 had a median annual CD4 cell count loss of 68 (...) cells/μl (P < 0.001). This suggests that HIV-1 virulence has increased over the course of the epidemic.

2016 AIDS

129. Immune activation in the central nervous system throughout the course of HIV infection. Full Text available with Trip Pro

Immune activation in the central nervous system throughout the course of HIV infection. Robust and dynamic innate and adaptive responses characterize the acute central nervous system (CNS) response to HIV and other viral infections. In a state of chronic infection or viral latency, persistent immune activation associates with abnormality in the CNS. Understanding this process is critical, as immune-mediated abnormality in nonrenewable CNS cells may result in long-term neurologic sequelae (...) for HIV-infected individuals.In humans, immune activation is reduced by suppressive combination antiretroviral therapy, but persists at abnormally elevated levels on treatment. CNS immune activation is initiated in acute infection and progressively increases until combination antiretroviral therapy is started. Newly identified characteristics of the CNS immune surveillance network include features of homeostasis and function of brain microglial cells, lymphatic drainage from CNS to cervical lymph

2016 Current opinion in HIV and AIDS

130. Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients Full Text available with Trip Pro

Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients Introduction. Pneumocystis pneumonia (PCP) is rising in the non-HIV population and associates with higher morbidity and mortality. The aggressive immunosuppressive regimens, as well as the lack of stablished guidelines for chemoprophylaxis, are likely contributors to this increased incidence. Herein, we have explored the underlying conditions, immunosuppressive therapies, and clinical (...) outcomes of PCP in HIV-negative patients. Methods. Retrospective analysis of PCP in HIV-negative patients at Mayo Clinic from 2006-2010. The underlying condition, immunosuppressive therapies, coinfection, and clinical course were determined. PCP diagnosis required symptoms of pneumonia and identification of the organisms by visualization or by a real-time polymerase chain reaction. Results. A total of 128 cases of PCP were identified during the study period. Hematological malignancies were

2016 Canadian respiratory journal

131. HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission Full Text available with Trip Pro

HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission Antiretroviral drug resistance following pMTCT strategies remains a significant problem. With rapid advancements in next generation sequencing technologies, there is more focus on HIV drug-resistant variants of low frequency, or the so-called minority variants. In South Africa, AZT monotherapy

2016 Journal of acquired immune deficiency syndromes (1999)

132. From First Love to Marriage and Maturity: A Life-Course Perspective on HIV Risk among Young Swazi Adults Full Text available with Trip Pro

From First Love to Marriage and Maturity: A Life-Course Perspective on HIV Risk among Young Swazi Adults This paper uses a life-course approach to explore the sexual partnerships and HIV-related risk of men and women in Swaziland throughout their adolescence, 20s and 30s. Twenty-eight Swazi men and women between the ages of 20 and 39 discussed their life histories in 117 in-depth interviews, with an average follow-up of nine months. Many participants described painful childhood experiences (...) and change was observed over the study period, with half of participants reporting concurrency within their primary relationship. Participants' narratives revealed significant sources and circumstances of risk, particularly multiple and concurrent sexual partnerships, violence and lack of mutual trust within relationships, as well as social ideals that may provide opportunities for effective HIV prevention.

2016 Culture, health & sexuality

133. Migration as a risk and a livelihood strategy: HIV across the life course of migrant families in India Full Text available with Trip Pro

Migration as a risk and a livelihood strategy: HIV across the life course of migrant families in India Migrant workers are understood to be vulnerable to HIV. However, little is known about the experience of migration-based households following HIV infection. This qualitative study examined the migration-HIV relationship beyond the point of infection, looking at how it affects livelihood choices, household relationships and the economic viability of migrant families. We conducted semi (...) and reduced physical strength. Insecure migrant job markets, monthly drug collection and discriminatory employment policies impeded future migration plans. HIV-positive wives of migrants occupied an insecure position in the rural marital household that depended on their husbands' health and presence of children. The migration-HIV relationship continued to shape the life course of migrant families beyond the point of infection, often exposing them again to the economic insecurity that migration had helped

2016 Global public health

134. Occupational HIV risk for health care workers: risk factor and the risk of infection in the course of professional activities Full Text available with Trip Pro

Occupational HIV risk for health care workers: risk factor and the risk of infection in the course of professional activities Virtually created panic among health care workers about pandemic acquired immune deficiency syndrome prompted us to review the scientific literature to investigate the risk of human immunodeficiency virus (HIV) transmission in the daily works of health care workers, especially surgeons and anesthesiologists. In this review, we report worldwide valuations of the number (...) of HIV infections that may occur from unsafe daily work in health care. We also present how to minimize the risk of infection by taking precautions and how to utilize postexposure prophylaxis in accordance with the latest reports of the Centers for Disease Control and Prevention. HIV-infected patients will be aging, and most of them will become the candidates for procedures such as major vascular reconstruction and artery bypass grafting, where the risks of blood contact and staff injury are high

2016 Therapeutics and clinical risk management

135. Antiretroviral Use for Prevention and Other Factors Affecting the Course of the HIV-1 Epidemic Full Text available with Trip Pro

Antiretroviral Use for Prevention and Other Factors Affecting the Course of the HIV-1 Epidemic Antiretroviral therapy has tremendous potential to alter the HIV-1 epidemic trajectory. However, gaps in the continuum from HIV diagnosis, through linkage to care and uptake and adherence to antiretroviral therapy, are substantially limiting to the actual impact. In the United States, gaps in HIV diagnosis and care are greatest among African Americans, substance users, and persons living below (...) the poverty line. Globally, HIV diagnosis rates are highest in women, but HIV incidence may be declining more rapidly in men, due to lower transmission rates from female partners and greater uptake of medical male circumcision. The 2012 Conference on Retroviruses and Opportunistic Infections explored gaps in the continuum of care and potential strategies to address them, and also addressed the disparate results from preexposure prophylaxis efficacy trials. The role of injectable contraceptives

2016 Topics in antiviral medicine

136. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. Full Text available with Trip Pro

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. We assessed factors, including treatment course, associated with failure to obtain a 10 year immunological response after starting first-generation PI-containing combined ART (cART).In the prospective COPILOTE cohort of HIV-infected patients started on a first-generation PI-containing regimen in 1997-99, the impact of cART history (...) response, despite prolonged virological success. Lack of treatment interruption may improve long-term immunological outcome in HIV infection.© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

2016 Journal of Antimicrobial Chemotherapy

137. Short-course antiretroviral therapy in primary HIV infection. Full Text available with Trip Pro

Short-course antiretroviral therapy in primary HIV infection. Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated.We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART for 12 weeks, or no ART (standard of care), with treatment initiated within 6 months after seroconversion. The primary end point was a CD4+ count of less than 350 cells per cubic millimeter (...) a greater interval between ART initiation and the primary end point the closer that ART was initiated to estimated seroconversion (P=0.09), and 48-week ART conferred a reduction in the HIV RNA level of 0.44 log(10) copies per milliliter (95% CI, 0.25 to 0.64) 36 weeks after the completion of short-course therapy. There were no significant between-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious adverse events.A 48-week course of ART in patients with primary

2013 NEJM Controlled trial quality: predicted high

138. Time-Course Analysis of Main Markers of Primary Infection in Cats with the Feline Immunodeficiency Virus Full Text available with Trip Pro

Time-Course Analysis of Main Markers of Primary Infection in Cats with the Feline Immunodeficiency Virus Studies of the response of the immune system to feline immunodeficiency virus (FIV) during primary infection have shown that a subpopulation of CD8(+) T-cells with an activated phenotype and reduced expression of the CD8β chain (denoted CD8β(low) T cells) expands to reach up to 80% of the total CD8(+) T cell count. The expansion of this subpopulation is considered to be a signature of FIV (...) with a population approach using data from 102 experimentally infected cats. We examine the dose of infection as a potential covariate of parameters. We find that the rates of increase of viral load and of CD8β(low) percentage are both correlated with the dose of infection. Cats that develop strong acute viremia also show the largest degree of CD8β(low) expansion. The two simple models are robust tools for analysing the time course of CD8β(low) percentage and circulating viral load in FIV-infected cats and may

2012 Computational and mathematical methods in medicine

139. Sexual and reproductive health and HIV: applying All Our Health

health and HIV. 25 January 2018 Updated the data in the guidance and linked to 'HIV in the UK: 2016 report' instead of '2014 HIV: surveillance, data and management report'. Added a new section about online courses. 4 August 2017 Updated measuring outcomes section to add links to Everyday Interactions measuring impact toolkit and sexual health impact pathway. 1 April 2015 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve (...) Sexual and reproductive health and HIV: applying All Our Health Sexual and reproductive health and HIV: applying All Our Health - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Sexual and reproductive health

2019 Public Health England

140. Economic evaluations of pre- and post-exposure prophylaxis for HIV

Columbia Centre for Excellence in HIV/AIDS. HIV post-exposure prophylaxis (PEP) guidelines: May 2017. Available from: Accessed November 30, 2018. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control Hospital Epidemiology. 2013;34(9):875–92. Hankins C, Macklin R, Warren M. Translating PrEP (...) prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Archives of Internal Medicine. 2004;164(1):46–54. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004;18(15):2065–73. Herida M, Larsen C, Lot F, Laporte A, Desenclos JC, Hamers FF. Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS. 2006;20

2019 Ontario HIV Treatment Network

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>